Evidence map›Paper›PMID 40553193›Full record

ReviewDermatologie (Heidelberg, Germany)2025

[Development of resistance in skin fungi : Molecular mechanisms, antifungal resistance assays, risk factors, and diagnostic regime-challenges for medical treatment].

Anke Burmester, Cornelia Wiegand

Abstract readEnglish AbstractReview
PubMed Publisher
In one paragraph

Review in Dermatologie (Heidelberg, Germany), 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

2 authors.

Anke BurmesterDermatologisches Forschungslabor, Laborleitung Dermatomykologische Diagnostik, Klinik für Hautkrankheiten, Universitätsklinikum Jena, Dermatologisches Forschungslabor Gebäude F2, Am Klinikum 1, 07747, Jena, Deutschland.
Cornelia WiegandDermatologisches Forschungslabor, Laborleitung Dermatomykologische Diagnostik, Klinik für Hautkrankheiten, Universitätsklinikum Jena, Dermatologisches Forschungslabor Gebäude F2, Am Klinikum 1, 07747, Jena, Deutschland. C.Wiegand@med.uni-jena.de.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The growing prevalence of resistant dermatophyte isolates, particularly from Trichophyton indotineae (synonym: T. mentagrophytes ITS genotype VIII) but also from T. rubrum may lead to increasing numbers of difficult-to-treat dermatomycoses. Terbinafine resistance in T. indotineae or T. rubrum is caused by point mutations that alter specific positions in the Erg1 gene encoding squalene epoxidase, thereby, preventing effective binding of terbinafine to the enzyme. In T. indotineae, two different forms of genomic amplification of Erg11B that lead to azole resistance have been identified. Like Erg11A, Erg11B encodes a form of sterol-14-α-demethylase, whose enzymatic activity is inhibited by azole binding. In T. indotineae as well as in T. rubrum, point mutations in Erg11B have been identified that result in altered amino acid sequences and prevent binding of specific classes of azoles. Another resistance mechanism involves increased expression of transporter proteins responsible for drug efflux. The combination of these various mechanisms presents a major challenge for diagnostics and requires adaptation of both the diagnostic approach and the subsequent therapeutic strategies.

Indexed as

Antifungal AgentsArthrodermataceaeDermatomycosesDrug Resistance, FungalAzolesHumansPoint MutationRisk FactorsSqualene MonooxygenaseTerbinafineAntifungal AgentsAzolesSqualene MonooxygenaseTerbinafineAzole resistanceDermatomycosesTerbinafine resistanceTrichophyton indotineaeTrichophyton rubrum

Identifiers

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.